Author: Zacks Small Cap Research

123456030 / 597 POSTS
By Steven Ralston, CFACSE:HUGE.CN | OTC:FSDDFREAD THE FULL HUGE.CN RESEARCH REPORTFSD Pharma Inc. (CSE:HUGE.CN) (OTC:FSDDF) is a cannabis-platform company which is targeting many verticals that compose the legal cannabis industry. The platform can be ...
By David Bautz, PhDNASDAQ:TNXPREAD THE FULL TNXP RESEARCH REPORTBusiness UpdatePipeline ExpansionIn the past few months, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has announced the addition of a number of new programs to its clinical and pre- ...
By Ann Heffron, CFA, CPAOTC:CPKFREAD THE FULL CPKF RESEARCH REPORTChesapeake Financial’s (OTC:CPKF) second quarter net earnings rose $0.4 million, or 14%, year over year to $3.3 million, while 2019’s second quarter diluted EPS increased by $0.10, or ...
By Ian Gilson, PhD, CFANASDAQ:EASTREAD THE FULL EAST RESEARCH REPORTEastside Distilling (NASDAQ:EAST) has acquired Azunia Tequila from its owners, Intersect Beverage. The cost was one point two million shares depending on certain future revenue proje ...
By Ian Gilson, PhD, CFANASDAQ:MBIIREAD THE FULL MBII RESEARCH REPORTMarrone (NASDAQ:MBII) has completed the acquisition of Pro Farm Technologies, a company with which they had previously signed an agreement to collaborate on the use of each other's p ...
By Brian Marckx, CFANASDAQ:RKDA | OTC:VAPNFREAD THE FULL RKDA RESEARCH REPORTSNAPSHOT: Anticipating Three Key Launches, Steepening Growth CurveArcadia Biosciences, Inc (NASDAQ:RKDA) is an innovative agricultural company with a broad and growing produ ...
By Brian Marckx, CFAOTC:SNWVREAD THE FULL SNWV RESEARCH REPORTQ2 Results, Operational Update: Record U.S. Product Sales. NGS Update Should Help Drive Adoption, Procedure Revenue ….SANUWAVE (OTC:SNWV) reported financial results for their second quarte ...
By David Bautz, PhDTSX:ATE.VREAD THE FULL ATE.V RESEARCH REPORTBusiness UpdatePhase 2b Study Results in 4Q19In March 2019, Antibe Therapeutics Inc. (TSX:ATE.V) announced that the Phase 2b dose-ranging, efficacy study of ATB-346 had commenced. It is a ...
By David Bautz, PhDNASDAQ:SNGXREAD THE FULL SNGX RESEARCH REPORTPositive Interim Analysis of SGX942 Phase 3 Clinical TrialOn August 28, 2019, Soligenix, Inc. (NASDAQ:SNGX) announced a positive recommendation from the independent Data Monitoring Commi ...
By David Bautz, PhDNASDAQ:SPHSREAD THE FULL SPHS RESEARCH REPORTBusiness UpdateSophiris Bio Inc. (NASDAQ:SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperpla ...
123456030 / 597 POSTS